Promis Neurosciences Stock Total Asset
| PMN Stock | USD 0.92 0.11 10.68% |
ProMIS Neurosciences fundamentals help investors to digest information that contributes to ProMIS Neurosciences' financial success or failures. It also enables traders to predict the movement of ProMIS Stock. The fundamental analysis module provides a way to measure ProMIS Neurosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ProMIS Neurosciences stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 18 M | 18.9 M |
ProMIS | Total Asset |
ProMIS Neurosciences Company Total Asset Analysis
ProMIS Neurosciences' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current ProMIS Neurosciences Total Asset | 18.04 M |
Most of ProMIS Neurosciences' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ProMIS Neurosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ProMIS Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for ProMIS Neurosciences is extremely important. It helps to project a fair market value of ProMIS Stock properly, considering its historical fundamentals such as Total Asset. Since ProMIS Neurosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ProMIS Neurosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ProMIS Neurosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
ProMIS Total Asset Historical Pattern
Today, most investors in ProMIS Neurosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ProMIS Neurosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ProMIS Neurosciences total asset as a starting point in their analysis.
ProMIS Neurosciences Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
ProMIS Total Assets
Total Assets |
|
Based on the latest financial disclosure, ProMIS Neurosciences has a Total Asset of 18.04 M. This is 99.76% lower than that of the Biotechnology sector and 99.09% lower than that of the Health Care industry. The total asset for all United States stocks is 99.94% higher than that of the company.
ProMIS Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ProMIS Neurosciences' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ProMIS Neurosciences could also be used in its relative valuation, which is a method of valuing ProMIS Neurosciences by comparing valuation metrics of similar companies.ProMIS Neurosciences is currently under evaluation in total asset category among its peers.
ProMIS Neurosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of ProMIS Neurosciences from analyzing ProMIS Neurosciences' financial statements. These drivers represent accounts that assess ProMIS Neurosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ProMIS Neurosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 43.8M | 29.1M | 48.3M | 32.6M | 14.1M | 13.4M | |
| Enterprise Value | 42.2M | 28.1M | 31.8M | 24.6M | (2.6M) | (2.4M) |
ProMIS Neurosciences Institutional Holders
Institutional Holdings refers to the ownership stake in ProMIS Neurosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ProMIS Neurosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ProMIS Neurosciences' value.| Shares | Sandy Spring Bank | 2024-06-30 | 3.3 K | Bank Of America Corp | 2024-06-30 | 1.7 K | Royal Bank Of Canada | 2024-06-30 | 713 | Td Waterhouse Canada Inc | 2024-06-30 | 133 | Wells Fargo & Co | 2024-06-30 | 20.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 4.0 | Jpmorgan Chase & Co | 2024-06-30 | 3.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Northeast Financial Consultants, Inc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 2.7 M | Sphera Funds Management Ltd. | 2024-09-30 | 1.9 M |
ProMIS Fundamentals
| Return On Equity | -10.99 | ||||
| Return On Asset | -4.81 | ||||
| Current Valuation | 8.5 M | ||||
| Shares Outstanding | 32.69 M | ||||
| Shares Owned By Insiders | 44.78 % | ||||
| Shares Owned By Institutions | 50.30 % | ||||
| Number Of Shares Shorted | 239.78 K | ||||
| Price To Book | 4.13 X | ||||
| Price To Sales | 5,168 X | ||||
| Gross Profit | (16.09 M) | ||||
| EBITDA | (17.81 M) | ||||
| Net Income | (17.51 M) | ||||
| Cash And Equivalents | 8.95 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 13.07 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 5.42 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (14.37 M) | ||||
| Short Ratio | 2.64 X | ||||
| Earnings Per Share | 0.04 X | ||||
| Target Price | 12.22 | ||||
| Beta | 0.61 | ||||
| Market Capitalization | 30.07 M | ||||
| Total Asset | 18.04 M | ||||
| Retained Earnings | (123.84 M) | ||||
| Working Capital | 490.44 K | ||||
| Net Asset | 18.04 M |
About ProMIS Neurosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProMIS Neurosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProMIS Neurosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProMIS Neurosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ProMIS Neurosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with ProMIS Stock
| 0.72 | ME | 23Andme Holding | PairCorr |
| 0.75 | VALN | Valneva SE ADR | PairCorr |
| 0.62 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against ProMIS Stock
| 0.79 | KZR | Kezar Life Sciences | PairCorr |
| 0.65 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.31 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ProMIS Neurosciences Piotroski F Score and ProMIS Neurosciences Altman Z Score analysis. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.